JP5014121B2 - ムスカリン性アセチルコリン受容体アンタゴニスト - Google Patents

ムスカリン性アセチルコリン受容体アンタゴニスト Download PDF

Info

Publication number
JP5014121B2
JP5014121B2 JP2007510915A JP2007510915A JP5014121B2 JP 5014121 B2 JP5014121 B2 JP 5014121B2 JP 2007510915 A JP2007510915 A JP 2007510915A JP 2007510915 A JP2007510915 A JP 2007510915A JP 5014121 B2 JP5014121 B2 JP 5014121B2
Authority
JP
Japan
Prior art keywords
methyl
hydroxy
azoniabicyclo
diphenyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007510915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007534769A (ja
Inventor
ドラマーヌ・イ・レーヌ
マイケル・アール・パロビッチ
ブレント・ダブリュー・マクルランド
クリストファー・イー・ニップ
ソニア・エム・トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5014121(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2007534769A publication Critical patent/JP2007534769A/ja
Application granted granted Critical
Publication of JP5014121B2 publication Critical patent/JP5014121B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
JP2007510915A 2004-04-27 2005-04-27 ムスカリン性アセチルコリン受容体アンタゴニスト Expired - Lifetime JP5014121B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27
US60/565,623 2004-04-27
PCT/US2005/014386 WO2005104745A2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012092339A Division JP5398871B2 (ja) 2004-04-27 2012-04-13 ムスカリン性アセチルコリン受容体アンタゴニスト

Publications (2)

Publication Number Publication Date
JP2007534769A JP2007534769A (ja) 2007-11-29
JP5014121B2 true JP5014121B2 (ja) 2012-08-29

Family

ID=35242158

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007510915A Expired - Lifetime JP5014121B2 (ja) 2004-04-27 2005-04-27 ムスカリン性アセチルコリン受容体アンタゴニスト
JP2012092339A Expired - Lifetime JP5398871B2 (ja) 2004-04-27 2012-04-13 ムスカリン性アセチルコリン受容体アンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012092339A Expired - Lifetime JP5398871B2 (ja) 2004-04-27 2012-04-13 ムスカリン性アセチルコリン受容体アンタゴニスト

Country Status (38)

Country Link
US (9) US7498440B2 (OSRAM)
EP (3) EP1740177B1 (OSRAM)
JP (2) JP5014121B2 (OSRAM)
KR (2) KR101152032B1 (OSRAM)
CN (2) CN1976701A (OSRAM)
AP (1) AP2213A (OSRAM)
AR (1) AR050902A1 (OSRAM)
AU (1) AU2005237576B2 (OSRAM)
BE (1) BE2014C063I2 (OSRAM)
BR (1) BRPI0510170B8 (OSRAM)
CA (2) CA2755954C (OSRAM)
CY (3) CY1113196T1 (OSRAM)
DK (2) DK1740177T3 (OSRAM)
EA (2) EA015033B1 (OSRAM)
EC (1) ECSP066940A (OSRAM)
ES (2) ES2600405T3 (OSRAM)
FR (1) FR14C0075I2 (OSRAM)
HR (2) HRP20120832T1 (OSRAM)
HU (2) HUE031304T2 (OSRAM)
IL (1) IL178152A (OSRAM)
LT (1) LT2570128T (OSRAM)
LU (1) LU92565I2 (OSRAM)
MA (1) MA28631B1 (OSRAM)
MX (1) MXPA06012405A (OSRAM)
MY (1) MY144753A (OSRAM)
NL (1) NL300694I1 (OSRAM)
NO (3) NO338959B1 (OSRAM)
NZ (1) NZ549997A (OSRAM)
PE (1) PE20060259A1 (OSRAM)
PL (2) PL1740177T3 (OSRAM)
PT (2) PT2570128T (OSRAM)
SG (1) SG186597A1 (OSRAM)
SI (2) SI2570128T1 (OSRAM)
TW (1) TWI363759B (OSRAM)
UA (1) UA95768C2 (OSRAM)
UY (1) UY28871A1 (OSRAM)
WO (1) WO2005104745A2 (OSRAM)
ZA (1) ZA200608565B (OSRAM)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AP2006003575A0 (en) * 2003-10-17 2006-04-30 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists.
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2007529511A (ja) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US7384946B2 (en) * 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
ATE405263T1 (de) * 2004-04-05 2008-09-15 Samaritan Pharmaceuticals Inc Anti-hiv-chinuklidinverbindungen
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
WO2006055553A2 (en) * 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2009503099A (ja) * 2005-08-02 2009-01-29 グラクソ グループ リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1937068A4 (en) * 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
AR060536A1 (es) 2006-04-20 2008-06-25 Glaxo Group Ltd Agonista del receptor de glucocorticoides y composiciones farmaceuticas
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
HRP20110434T1 (hr) 2006-08-01 2011-08-31 Glaxo Group Limited Spojevi pirazolo[3,4-b]piridina i njihova upotreba kao inhibitora pde4
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
PE20091552A1 (es) 2008-02-06 2009-10-25 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
PE20091563A1 (es) 2008-02-06 2009-11-05 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
ATE552255T1 (de) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
TWI516487B (zh) 2009-04-30 2016-01-11 葛蘭素集團有限公司 新穎化合物、其醫藥組合物及作為激酶活性抑制劑之用途
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
WO2011094434A2 (en) * 2010-01-28 2011-08-04 Theron Pharmaceuticals, Inc. 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
MA34326B1 (fr) * 2010-06-22 2013-06-01 Chiesi Farma Spa Formulation de poudre sèche comprenant un médicament antimuscarinique
PL2614058T3 (pl) 2010-09-08 2015-12-31 Glaxosmithkline Ip Dev Ltd Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US20140113888A1 (en) * 2011-06-08 2014-04-24 Glaxo Group Limited Novel Combination of Therapeutic Agents
AU2012266540A1 (en) 2011-06-08 2014-01-09 Glaxo Group Limited Dry powder inhaler compositions comprising umeclidinium
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
CA2881935A1 (en) 2012-08-15 2014-02-20 Glaxo Group Limited Process for preparing a 1-(2-haolethyl)-4-piperidine carboxylate intermediate useful in the synthesis of umeclidinium bromide
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
AU2014292722B2 (en) 2013-07-13 2017-03-09 Beijing Showby Pharmaceutical Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
EP3027184A1 (en) 2013-07-30 2016-06-08 GlaxoSmithKline Intellectual Property Development Limited Topical compositions for treatment of excessive sweating and methods of use thereof
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CA2925064A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
WO2015181262A1 (en) 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd
WO2016071792A1 (en) 2014-11-03 2016-05-12 Laboratorio Chimico Internazionale S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
EP3400214B1 (en) * 2016-01-08 2024-03-13 Theron Pharmaceuticals, Inc. Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
PT109740B (pt) 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
SG11202003793WA (en) 2017-10-30 2020-05-28 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
CN116194114A (zh) 2020-03-26 2023-05-30 葛兰素史密斯克莱知识产权发展有限公司 用于防止或治疗病毒感染的组织蛋白酶抑制剂
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
AU2021264829B2 (en) 2020-04-26 2024-02-01 Beijing Showby Pharmaceutical Co., Ltd. Crystal of M receptor antagonist as well as preparation method therefor and application thereof
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V Antibody fragment against fap
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
WO2024251812A1 (en) 2023-06-07 2024-12-12 Pharmazell Gmbh A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) * 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (OSRAM) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
LU85034A1 (fr) 1982-10-08 1985-06-19 Glaxo Group Ltd Dispositifs en vue d'administrer des medicaments a des patients
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) * 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
US6350758B1 (en) * 1996-12-02 2002-02-26 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) * 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
PT1353919E (pt) * 2000-12-28 2006-11-30 Almirall Prodesfarma Ag Novos derivados de quinuclidina e composições medicinais contendo os mesmos
PL370087A1 (en) * 2001-10-17 2005-05-16 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
JP2005510523A (ja) * 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
WO2003053966A2 (en) * 2001-12-20 2003-07-03 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
EP1613307A4 (en) 2003-04-07 2008-03-12 Glaxo Group Ltd M SB 3 / SB MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
TW200519108A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
UY28417A1 (es) 2003-07-17 2005-02-28 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
TW200519109A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
PE20050963A1 (es) 2003-10-14 2006-01-11 Glaxo Group Ltd Compuestos derivados de 8-azoniabiciclo [3.2.1]octanos como antagonistas de receptores de acetilcolina muscarinicos
AP2006003575A0 (en) 2003-10-17 2006-04-30 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists.
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
US7345060B2 (en) * 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200530226A (en) 2003-12-03 2005-09-16 Glaxo Group Ltd Novel M3 muscarinic acetylcholine receptor antagonists
UY28645A1 (es) 2003-12-03 2005-06-30 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005087236A1 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US20070179131A1 (en) 2004-03-11 2007-08-02 Jian Jin Novel M3 Muscarinic Acetylcholine Receptor Antagonists
EP1725241A4 (en) 2004-03-17 2009-03-25 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC M3 RECEPTOR
JP2007529512A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007529511A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US7384946B2 (en) 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005099706A2 (en) 2004-04-07 2005-10-27 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
AR050902A1 (es) * 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
JP2007537261A (ja) 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
PE20060367A1 (es) 2004-05-28 2006-04-28 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1]octanos como antagonistas del receptor de acetilcolina muscarinico
WO2006005057A2 (en) 2004-06-30 2006-01-12 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
JP2008509159A (ja) 2004-08-05 2008-03-27 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体拮抗薬
US20090076061A1 (en) 2004-08-06 2009-03-19 Jakob Busch-Petersen Muscarinic acetycholine receptor antagonists
JP2008518939A (ja) 2004-10-29 2008-06-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
EP1827439A4 (en) 2004-11-15 2009-11-18 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
WO2006055553A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
JP2009503099A (ja) 2005-08-02 2009-01-29 グラクソ グループ リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2007016650A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1937068A4 (en) 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
HK1102423A1 (en) 2007-11-23
EP3111936A1 (en) 2017-01-04
EA201100019A1 (ru) 2011-12-30
JP2012162559A (ja) 2012-08-30
WO2005104745A2 (en) 2005-11-10
US20150238470A1 (en) 2015-08-27
US20090124653A1 (en) 2009-05-14
LU92565I2 (fr) 2014-12-02
LU92565I9 (OSRAM) 2019-01-17
US7498440B2 (en) 2009-03-03
CY2014043I2 (el) 2015-12-09
BRPI0510170B8 (pt) 2021-05-25
PT1740177E (pt) 2012-11-02
KR101037026B1 (ko) 2011-05-25
EA200601991A1 (ru) 2007-02-27
HUS1400053I1 (hu) 2017-07-28
CY1113196T1 (el) 2015-12-09
HRP20161385T1 (hr) 2016-12-02
EA021994B1 (ru) 2015-10-30
JP5398871B2 (ja) 2014-01-29
EP1740177A2 (en) 2007-01-10
ECSP066940A (es) 2006-12-20
MA28631B1 (fr) 2007-06-01
FR14C0075I2 (fr) 2015-05-22
JP2007534769A (ja) 2007-11-29
CA2755954A1 (en) 2005-11-10
NL300694I2 (OSRAM) 2015-12-29
TWI363759B (en) 2012-05-11
CN1976701A (zh) 2007-06-06
CA2755954C (en) 2014-02-18
AP2006003746A0 (en) 2006-10-31
UY28871A1 (es) 2005-11-30
DK1740177T3 (da) 2012-10-29
IL178152A0 (en) 2006-12-31
US20160002220A1 (en) 2016-01-07
EP2570128B1 (en) 2016-08-10
WO2005104745A3 (en) 2006-08-03
LT2570128T (lt) 2016-10-10
CA2564742C (en) 2012-01-10
US20070185155A1 (en) 2007-08-09
NO2017017I1 (no) 2017-05-04
AU2005237576B2 (en) 2012-01-12
CY1118082T1 (el) 2017-06-28
US9045469B2 (en) 2015-06-02
AU2005237576A1 (en) 2005-11-10
CY2014043I1 (el) 2015-12-09
FR14C0075I1 (fr) 2014-11-21
SI2570128T1 (sl) 2016-11-30
SI1740177T1 (sl) 2012-12-31
CA2564742A1 (en) 2005-11-10
US20140371264A1 (en) 2014-12-18
NL300694I1 (OSRAM) 2015-12-29
PE20060259A1 (es) 2006-03-25
US8575347B2 (en) 2013-11-05
PL2570128T3 (pl) 2017-09-29
KR101152032B1 (ko) 2012-06-11
NO20065417L (no) 2006-12-29
US8853404B2 (en) 2014-10-07
HUE031304T2 (hu) 2017-07-28
UA95768C2 (ru) 2011-09-12
DK2570128T3 (en) 2016-11-07
EP1740177A4 (en) 2010-05-05
US20130030015A1 (en) 2013-01-31
CN102040602A (zh) 2011-05-04
NZ549997A (en) 2010-10-29
ES2392848T4 (es) 2014-10-01
TW200605887A (en) 2006-02-16
BRPI0510170B1 (pt) 2018-12-18
IL178152A (en) 2011-05-31
MXPA06012405A (es) 2007-01-17
AP2213A (en) 2011-03-01
KR20070015412A (ko) 2007-02-02
US7488827B2 (en) 2009-02-10
US9144571B2 (en) 2015-09-29
ES2600405T3 (es) 2017-02-08
BE2014C063I2 (OSRAM) 2024-08-08
NO2017018I1 (no) 2017-05-04
EP2570128A1 (en) 2013-03-20
US8309572B2 (en) 2012-11-13
KR20110010841A (ko) 2011-02-07
PL1740177T3 (pl) 2012-12-31
US8183257B2 (en) 2012-05-22
BRPI0510170A (pt) 2007-10-02
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
EP1740177B1 (en) 2012-08-08
ES2392848T3 (es) 2012-12-14
NO2017018I2 (no) 2018-05-14
AR050902A1 (es) 2006-12-06
EA015033B1 (ru) 2011-04-29
MY144753A (en) 2011-10-31
HRP20120832T1 (hr) 2012-11-30
PT2570128T (pt) 2016-10-07
US20120157491A1 (en) 2012-06-21
NO338959B1 (no) 2016-11-07
ZA200608565B (en) 2019-12-18
SG186597A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
JP5014121B2 (ja) ムスカリン性アセチルコリン受容体アンタゴニスト
US7767691B2 (en) Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
US7598267B2 (en) Muscarinic acetylcholine receptor antagonists
AU2012202307B2 (en) Muscarinic acetylcholine receptor antagonists
HK1102423B (en) Muscarinic acetylcholine receptor antagonists

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110509

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120515

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120605

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150615

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5014121

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350